Projectes destacats

  • Epithelioid Hemangioendothelioma International Network

    Investigador/a principal: Jordi Rimola, María Reig Monzón.
    Finançador: European Association for the Study of the Liver - EASL .
    Codi: EHIN.
    Durada: 01/06/2021 - 01/06/2026
    Resum:

    Project Title: Epithelioid Hemangioendothelioma International Network Project reference: N/A PI: Jordi Rimola Funding Agency: EASL Funding: 50000 eur Duration: 2021-2026

  • A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

    Investigador/a principal: Jordi Bruix Jordi Rimola.
    Finançador: European Union in the framework of the Public Health Programme .
    Codi: EUCAN Image.
    Durada: 01/10/2020 - 31/10/2024
    Resum:

    October 2020. Grant sponsored by European Commission, H2020. PI: Jordi Rimola and Jordi Bruix Research Project: EuCanImage. A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology. Code: 952103 Quantity: 467.500 € Duration: 4 years (2020-2024).

  • A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

    Investigador/a principal: Jordi Rimola Gibert, Jordi Bruix Tudo.
    Finançador: European Union in the framework of the Public Health .
    Durada: 01/10/2020 - 31/10/2024
  • "Improving immunotherapy in hepatocellular carcinoma via PD-1-TGFβ cotargeting"

    Investigador/a principal: María Reig Monzón.
    Finançador: CIBEReHD .
    Codi: 20PI04.
    Durada: 02/04/2020 - 01/04/2022
    Resum:

    Proyecto Competitivo Ciber. 

  • Importancia del inflamasoma en la sensibilidad o resistencia a los inhibidores tirosina quinasa en pacientes con cáncer de hígado (PI18/00358) ( Importance of the inflammasome in the sensitivity or resistance to tyrosine kinase inhibitors in patients with

    Investigador/a principal: María Reig Monzón.
    Finançador: Instituto de Salud Carlos III .
    Durada: 01/01/2019 - 31/12/2022
  • Rendimiento de la RM con ácido gadoxético para el diagnóstico y estadiaje del carcinoma hepatocelular

    Investigador/a principal: Alejandro Forner Gonzalez.
    Finançador: Instuto de Salud Carlos III ; Hospita Clinic de Barcelona (Sede).
    Codi: PI18/00542.
    Durada: 01/01/2019 - 31/12/2021
  • AECC Clínico 2018: Prospective clinical evaluation of the genetic-immuno / inflammatory profile in the treatment of hepatocellular carcinoma with sorafenib to predict tolerance and survival"

    Investigador/a principal: Alvaro Díaz González, María Reig Monzón.
    Finançador: Asociación Española Contra el Cáncer (AECC). ; Asociación Española Contra el Cáncer (AECC) .
    Codi: CLJUN18016DIAZ.
    Durada: 01/08/2018 - 31/12/2019
  • A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

    Investigador/a principal: Jordi Bruix Tudo.
    Finançador: Adaptimmune .
    Codi: ADP-0033-001.
    Durada: 01/01/2018 - 31/12/2033
  • La inhibición de miR122 como evento precoz en el desarrollo de carcinoma hepatocelular en pacientes infectados por el virus de la hepatitis C. Papel de miR122 en el sistema inmunitario.

    Investigador/a principal: Loreto Boix Ferrero, Jordi Bruix Tudo.
    Finançador: Instituto de Salud Carlos III (ISCIII) .
    Codi: PI18/00768.
    Durada: 01/01/2018 - 31/03/2022
  • Analysis of potential changes in antitumor immune activity in patients with hepatocellular carcinoma after C virus erradication with direct antiviral agents (GLD/00095)

    Investigador/a principal: Mercedes Iñairraraegui, María Reig Monzón.
    Finançador: Gilead Sciences, S.L .
    Durada: 01/01/2017 - 01/01/2019